1. Partners in crime: The feedback loop between metabolic reprogramming and immune checkpoints in the tumor microenvironment
   Jesus J. Benito-Lopez et al, 2023, Frontiers in Oncology CrossRef
2. Functional Diversities of Regulatory T Cells in the Context of Cancer Immunotherapy
   Ran Gao et al, 2022, Frontiers in Immunology CrossRef
3. Immune modulatory roles of radioimmunotherapy: biological principles and clinical prospects
   Xuefeng Wang et al, 2024, Frontiers in Immunology CrossRef
4. Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond
   Yun Hua Lee et al, 2020, Frontiers in Immunology CrossRef
5. Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome
   R. Zou et al, 2021, Clinical and Translational Oncology CrossRef
6. Reprogramming of regulatory T cells in inflammatory tumor microenvironment: can it become immunotherapy turning point?
   Jinming Liu et al, 2024, Frontiers in Immunology CrossRef
7. IDO1 Activity Predicts Lung Toxicity in Patients with Unresectable Stage III NSCLC and Chemoradiotherapy
   Linfang Wu et al, 2023, Journal of Oncology CrossRef
8. Trial watch: IDO inhibitors in cancer therapy
   Julie Le Naour et al, 2020, OncoImmunology CrossRef
9. Research Progress on the Relationship between Tumor Radiotherapy and TIM-3
   晨晨 矫, 2022, Advances in Clinical Medicine CrossRef
10. Interleukin-6 and indoleamine-2,3-dioxygenase as potential adjuvant targets for Papillomavirus-related tumors immunotherapy
    Roberta Liberato Pagni et al, 2022, Frontiers in Immunology CrossRef
11. Dynamic change of IDO1 activity predicts survival in patients with unresectable stage III NSCLC and chemoradiotherapy
    Linfang Wu et al, 2022, Frontiers in Immunology CrossRef
12. Sodium Tanshinone IIA Sulfonate as a Potent IDO1/TDO2 Dual Inhibitor Enhances Anti-PD1 Therapy for Colorectal Cancer in Mice
    Rongjie Zhang et al, 2022, Frontiers in Pharmacology CrossRef